Other molecules involved in this pathway include lymphocyte activation gene (LAG)-3 and T-cell immunoglobulin and mucin-domain containing 3 (TIM-3) which is expressed on different T regulatory cells than PD-1 and thus hypothetically could be used in combination with anti-PD-1 therapy in cHL to promote effective tumour infiltration (90). The gene discussed is LAG3; the disease is neoplasm.